Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Opioid Dependence
Interventions: Memantine, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 25 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Aging, Skeletal Muscle
Interventions: Non-Exercise Control, Resistance Exercise Training, Placebo, HMB+VitD; Behavioral · Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Drug Abuse
Interventions: 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Early Alzheimer's Disease
Interventions: CT1812, Placebo; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more

Conditions: Hypertension
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Foley, Alabama • Buena Park, California • Carmichael, California + 42 more

Conditions: Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more

Conditions: Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Interventions: Psliocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Intellectual Disability, Fragile X Syndrome, Down Syndrome, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate Oral Solution; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 6 Years to 24 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Cincinnati, Ohio

Conditions: Overactive Bladder Syndrome
Interventions: V117957, Placebo; Drug
Lead sponsor: Imbrium Therapeutics; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Tucson, Arizona • Canoga Park, California • Long Beach, California + 9 more

Conditions: Alcohol Use Disorder
Interventions: ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: E2025, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Covid19
Interventions: Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo, Part B: Upamostat 200 or 400 mg; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 11
States / cities: Cutler Bay, Florida • Hialeah, Florida • Miami, Florida + 7 more

Conditions: Metastatic Colorectal Cancer
Interventions: Tivantinib, Placebo, Cetuximab, Irinotecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 24
States / cities: Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more

Conditions: Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage; Drug · Device · Diagnostic Test + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease, Cardiovascular Disease
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: SAR441566, Placebo, Ciprofloxacin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Pharmacokinetics of Fidaxomicin, Healthy Subjects
Interventions: Fidaxomicin, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Obstructive Sleep Apnea
Interventions: TAK-925, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 67 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more

Conditions: RSV Infection
Interventions: EDP-323, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Alcohol Use Disorder (AUD), Alcoholism
Interventions: Ibudilast, Medical management, Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cocaine Use Disorder
Interventions: Semaglutide, Placebo, cognitive behavioral therapy (CBT).; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 12 more

Search by objective public record fields.

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

Independent and Combined Effects of Resistance Exercise Training and β-hydroxy β-methylbutyrate Plus Vitamin D

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Effect of Febuxostat on Blood Pressure

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

Psilocybin Microdosing on Cognition, Mood and Quality of Life

Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

Study of V117957 in Overactive Bladder Syndrome

Development of a Selective ALDH2 Inhibitor to Treat AUD

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Effect of Alpelisib in Healthy Volunteers

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A Study of EDP-323 in Healthy Subjects

Ibudilast for Treating Alcohol Use Disorder

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis